Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback

Executive Summary

The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.

You may also be interested in...



J&J Plans 10 Potential Blockbuster Filings By 2023

The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.

J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns

The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel